22-LUN-127-AZ: A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Fo

Grants and Contracts Details

StatusActive
Effective start/end date5/12/222/28/23

Funding

  • AstraZeneca Pharmaceuticals LP (domestic): $16,931.00